ecancermedicalscience

Submit article

https://doi.org/10.3332/ecancer.2016.627

Abstract | Full Article | |

Clinical Study

Diagnostic and therapeutic update of mantle cell lymphoma (MCL): analysis of seven cases treated in a centre in one year

17 Mar 2016

Carmen Herrero-Vicent, Isidro Machado, Carmen Illueca, Amparo Avaria, Claudia Salazar, Abraham Hernandez, Sergio Sandiego, Javier Lavernia

Mantle cell lymphoma (MCL) is an infrequent subtype of non-Hodgkin’s lymphoma (NHL) and represents between 4–8% of adult lymphomas. Recently an increase in its incidence to 1–2 cases/100,000 inhabitants/year has been observed. The first line of treatment is based on chemoimmunotherapy and depends on age and the initial stage at diagnosis. There are no second line or successive treatments. There are currently several drugs available that provide acceptable results.

Article metrics: 7441 views

2049

5392

2155-the-influence-of-caregiver-type-on-isolation-distress-and-care-satisfaction-in-hematopoietic-stem-cell-transplant-patients-the-mediating-role-of-relationships

Research: The influence of caregiver type on isolation distress and care satisfaction in hematopoietic stem cell transplant patients: the mediating role of relationships

Anjali Rathee, Priyanshi Dixit, Surya Kant Tiwari, Mukul Aggarwal, Pradeep Kumar, Rishi Dhawan, Richa Chauhan, Jasmita Dass, Ganesh Kumar Vishwanathan, Tulika Seth, Manoranjan Mahapatra

25 Jun 2026

https://doi.org/10.3332/ecancer.2026.2155

Abstract | Full Article | PDF

2153-breaking-barriers-in-cancer-pain-management-a-report-from-the-national-week-against-cancer-pain-in-argentina-2025

Conference Report: Breaking barriers in cancer pain management: a report from the National Week Against Cancer Pain in Argentina 2025

Ariel Cherro, Laura Aresca, María Susana Ciruzzi, Alejo Agranatti, María Fernanda Montaña, Cynthia Frahne, Jaqueline Cimerman

23 Jun 2026

https://doi.org/10.3332/ecancer.2026.2153

Abstract | Full Article | PDF

2150-safety-of-immune-checkpoint-inhibitors-in-a-diverse-patient-population-a-single-institution-experience

Short Communication: Safety of immune checkpoint inhibitors in a diverse patient population: a single-institution experience

Grace M Ferri*, John F Murphy*, Akash Oza*, Alexander J B Bulteel, Wafaa Abbasi, Rachel Anderson, Mehmed Taha Dinc, Eva Gaufberg, Kayra Cengiz, Sainikhil Sontha, Janice Weinberg, Patrick Kurpaska, Yashvin Onkarappa Mangala, Matthew Kulke, Umit Tapan

18 Jun 2026

https://doi.org/10.3332/ecancer.2026.2150

Abstract | Full Article | PDF

2144-use-of-low-dose-immune-checkpoint-inhibitors-in-low-and-middle-income-countries-a-national-survey-of-oncologists-and-hematologists-in-mexico

Research: Use of low-dose immune checkpoint inhibitors in low- and middle-income countries: a national survey of oncologists and hematologists in Mexico

Andres Meraz-Brenez, Enrique Soto-Perez-De-Celis, Roberta Demichelis-Gomez, Leonardo Verduzco-Rodriguez, Arjun Gupta, Meera Ragavan, Fumiko Chino, Haydee Cristina Verduzco-Aguirre

10 Jun 2026

https://doi.org/10.3332/ecancer.2026.2144

Abstract | Full Article | PDF